Terren Scott Peizer | |
---|---|
Born | [1] | July 31, 1959
Alma mater | Wharton School of the University of Pennsylvania (B.S., Economics) |
Occupation | Businessperson |
Years active | 1983-present |
Known for |
|
Criminal charges | insider trading and securities fraud (2023) |
Terren Scott Peizer (born July 31, 1959) is an American businessperson. [2] He was the CEO and chairman of Ontrak Inc., a publicly traded healthcare company, but resigned in March 2023 after US authorities charged him with insider trading and securities fraud. [1] [3] [4] He formerly worked as a junk bond salesman at Drexel Burnham Lambert, and ultimately testified against his former boss Mike Milken in Milken's securities fraud prosecution, in exchange for immunity from both criminal prosecution and SEC sanctions. [5] He also held executive positions in small-cap technology, debt collection, bicycle tire, shoe importing, and biotech companies. [6] [7]
Peizer's hometown is Beachwood, Ohio. [8] He attended Beachwood High School. [9] Peizer graduated with an undergraduate B.S. in Economics from the Wharton School of the University of Pennsylvania. [2] [10] [11] He resides in Puerto Rico and Santa Monica, California. [1]
Out of college in 1983, Peizer worked for a few months at Goldman Sachs when he was 21 years old. [12] [10] Later that year he worked for a stint at First Boston as a high yield bond salesman. [12]
Michael Milken hired Peizer as a junk bond salesman at Drexel Burnham Lambert in 1985. [13] [14] His job was to manage the Drexel account of the president of high-yield mutual fund manager Solomon Asset Management, with whom Drexel had an illegal arrangement that included insider trading and phony tax losses. [15] [16] [17] [8] [18] [19] Peizer worked directly under (and at the same desk as) Milken and admired him, sometimes pretending to be him on the phone, and calling him "Dad". [20]
When investigations into Milken's illegal activities began, Peizer starting in 1988 provided material evidence to prosecutors against Milken and Solomon. [21] At Milken's pre-sentencing hearing for securities fraud in 1990, Peizer testified against Milken in exchange for immunity from both criminal prosecution and SEC sanctions. [6] [22] [18] [13] [12]
After Drexel, Peizer became a private investor in a series of small companies. [13]
In 1989 Peizer purchased the Omaha Racers, a minor league basketball team, but it struggled financially. [23] He sold the team the following year. [24]
In 1991 he gained control of plastics company UTI Chemicals Inc., which had 26 employees, and became its president for a salary of $100,000; the company had a loss of over three million dollars each of the following two years. [25] [26] He stepped down as its chairman in 1994. [27]
In June 1991 Peizer purchased $3.5 million of convertible debentures from Candies, Inc. (formerly known as Millfeld Trading Co.; a shoe importing and marketing business), and became a director of the company. [28] [29] He had by that time already purchased 135,000 shares of the company's common stock, and when he became a director he received warrants to purchase 1.1 million shares of the company's common stock at $10.00 per share. [28] [13] Peizer divested himself of over 90% of his stock in the company on September 23, 1991, one day before the company publicly acknowledged that it had materially underpaid its customs obligations and faced a $1.6 million liability. [28] In early 1992, the price of the company stock collapsed after the company disclosed that it was being investigated by federal prosecutors for systematic underpayment of its customs duties, and Peizer thereafter resigned as a director. [28]
Peizer purchased an interest of over 50% in Urethane Technologies, a small-cap company which manufactured and sold a bicycle tire that it claimed would not go flat, and named himself Chairman. [5] [30] He sold his shares in 1993 at what was reported to be a $6 million profit, and the company never delivered, lost money, and went bankrupt in 1997. [5] [31]
In 1993 he acquired a 37% share of now-defunct computer parts producer CMS Enhancements. He was elected chairman of the company, and held the position for two years. [32]
In the mid-1990s Peizer played a role in now-defunct Towers Financial Corporation. The company was a debt collection agency Ponzi scheme founded by fraudster Steven Hoffenberg, with which Jeffrey Epstein was involved. [13] [33] [34]
Peizer purchased an interest in Advanced Promotion Technologies, which manufactured electronic barcode coupon machines for checkout lines. [5] He subsequently sold his shares, and the company then went bankrupt in 1996. [5]
From 1997 to 1999, Peizer was president of Hollis-Eden, a startup pharmaceutical company. [13] [5] [35] The New York Times covered the company and his involvement in it in an article entitled: "No Sales, but Watch the Stock Soar". [13] By 1998 the company still had no sales or earnings. [13] That year Peizer said: "This is a once in a lifetime opportunity for me. We have something special." [31] Peizer resigned from the company in March 1999 concurrently with the dismissal of its CEO Richard B. Hollis for cause. [5] [13] [35] By September 1999 the company's stock was at $13.50, 47% lower than its 52-week high. [36]
In 1999 Peizer raised money for and invested in Tera Computer Company, an unprofitable 112-employee manufacturer of supercomputers. [37] [38] The money that was raised allowed Tera to later buy the remains of Cray Research, and Peizer was its chairman and a director from 1999 to 2000. [39] [40] [41] [42] He stepped down as chairman in 2000. [43] Tera said the reason was that Peizer would otherwise have been required to obtain a security clearance from the US Department of Defense by the end of 2000 to transfer Cray's classified government business to Tera by then, and Tera did not think that would happen. [43]
In 2004 Peizer founded Hythiam Inc., a tiny pharmaceutical company, from which in 2006 when he was majority shareholder he received $1.3 million in compensation. [44] [36] [45] The firm bought the rights to an ineffective addiction treatment, and marketed it. [46] Despite the fact that no placebo-controlled or double-blind study or peer-reviewed publication of its "Prometa" (the marketing name for Gabasync) approach had been undertaken, and although no FDA approval had been obtained, Hythiam advertised the "innovative, medically based treatment" (which could cost $15,000 per patient) and franchised doctors to use Prometa, in exchange for a per-patient fee. [47] [36] Barrons , in a November 2005 article entitled "Curb Your Cravings For This Stock", wrote "If the venture works out for patients and the investing public, it'll be a rare success for Peizer, who's promoted a series of disappointing small-cap medical or technology stocks ... since his days at Drexel". [36] Peizer said: "Hythiam is my biggest triumph. If it's the only thing I did, then my life would have been a tremendous success." [9] Journalist Scott Pelley said to him in 2007: "Depending and who you talk to, you're either a revolutionary or a snake oil salesman." [47] 60 Minutes , NBC News , and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing to market Prometa; the addiction drug proved to be completely ineffective. [31] [48] [49] [50] Journalist Adam Feuerstein opined: "most of what Peizer says is dubious-sounding hype". [51] In June 2008, Hythiam had generated a net loss each year for 5 straight years, and while its stock had traded at $61.26 a share in 2007, it traded at $0.18 per share three years later (a 99.7% drop). [52] [53] [54] According to independent investment research firm Morningstar: "Over the long haul, this company has posted some of its industry's worst returns on assets." [52]
In 2018, Peizer became CEO and chairman of BioVie, a pharmaceutical company of which he was majority shareholder (his ownership was 88% as of June 2021). [55] [56] In 2021 the company entered into an agreement to buy a product from another company he controlled, NeurMedix, for up to $10 million and over 8 million BioVie shares; that led to a 15% share price drop in one day to $18.30 a share, and in April 2023 the company's share price was down to $8.08. [57] [58] [59] He resigned on March 2, 2023, the day after he was criminally indicted, at which point the company had not yet received any revenue, and had lost $26 million in 2022. [60] [55]
In March 2021 Peizer became the controlling shareholder and board Executive Chairman of EVmo, a technology-enabled fleet management and rental company, which had a share price of $5.45 the prior month. [61] [62] [63] He resigned as EVmo Chairman on February 17, 2023, as the company defaulted on a $7.5 million loan, and its stock price had declined to $0.17 per share. [62] [63] [61]
He is the founder and CEO of Acuitas Group Holdings (of which he is the sole shareholder), biotech company NeurMedix (of which he was the sole shareholder, and which in 2021 made a multi-million dollar sale to BioVie, of which Peizer was CEO), and blockchain company Casperlabs. [10] [64]
Until his 2023 indictment, he was CEO and chairman of Catasys, Inc. (later renamed Ontrak Inc.), a publicly traded healthcare company that he had founded in 2003. [65] [12] [66] His 2018 compensation at the company was $2.4 million, over twice that of CEOs of similar companies. [67]
On March 1, 2023, Peizer was charged with insider trading by the SEC, which alleged that he sold $20 million of Ontrak Inc. stock in 2021 while he was in possession of material nonpublic negative information related to the company's largest customer. [66] [68] [69] Ontrak shares, which had traded at $85.21 in February 2021, were trading at under $1.00 since July 2022. [12] [70] In addition, the U.S. Department of Justice announced criminal charges of insider trading and securities fraud against Peizer, charging that thereby he had avoided $12 million in losses; Peizer was arrested. [1] [68] [12] [71] His case is assigned to the U.S. District Court for the Central District of California, before U.S. District Judge Dale S. Fischer. [1]
On March 2, 2023, he resigned as Ontrak CEO and Chairman. [3] If convicted, Peizer could face up to 65 years in prison. [72]
On January 31, 2024, a superseding indictment was filed, 2024 charging Peizer with additional counts of securities fraud and insider trading. [73]
On February 9, 2024, Peizer moved to dismiss the indictment. [74] On March 7, 2024, Judge Fischer denied Peizer’s motion to dismiss, holding that the government had alleged facts sufficient to give rise to a charge of insider trading. [74] Trial was set for June 4, 2024. [73]
Insider trading is the trading of a public company's stock or other securities based on material, nonpublic information about the company. In various countries, some kinds of trading based on insider information are illegal. This is because it is seen as unfair to other investors who do not have access to the information, as the investor with insider information could potentially make larger profits than a typical investor could make. The rules governing insider trading are complex and vary significantly from country to country. The extent of enforcement also varies from one country to another. The definition of insider in one jurisdiction can be broad and may cover not only insiders themselves but also any persons related to them, such as brokers, associates, and even family members. A person who becomes aware of non-public information and trades on that basis may be guilty of a crime.
Michael Robert Milken is an American financier. He is known for his role in the development of the market for high-yield bonds, and his conviction and sentence following a guilty plea on felony charges for violating U.S. securities laws. Milken's compensation while head of the high-yield bond department at Drexel Burnham Lambert in the late 1980s exceeded $1 billion over a four-year period, a record for U.S. income at that time. With a net worth of US$6 billion as of 2022, he is among the richest people in the world.
The 2003 mutual fund scandal was the result of the discovery of illegal late trading and market timing practices on the part of certain hedge fund and mutual fund companies.
Charles Christopher Cox is an American attorney and politician who served as chair of the U.S. Securities and Exchange Commission, a 17-year Republican member of the United States House of Representatives, and member of the White House staff in the Reagan Administration. Prior to his Washington service he was a practicing attorney, teacher, and entrepreneur. Following his retirement from government in 2009, he returned to law practice and currently serves as a director, trustee, and advisor to several for-profit and nonprofit organizations.
Ivan Frederick Boesky is a former American stock trader who became infamous for his prominent role in an insider trading scandal that occurred in the United States during the mid-1980s. He was charged and pled guilty to insider trading, was fined a record $100 million, served three years in prison and became an informant.
GameStop Corp. is an American video game, consumer electronics, and gaming merchandise retailer. The company is headquartered in Grapevine, Texas, and is the largest video game retailer worldwide. As of January 28, 2023, the company operates 4,413 stores including 2,949 in the United States, 216 in Canada, 419 in Australia and 829 in Europe under the GameStop, EB Games, EB Games Australia, Micromania-Zing, ThinkGeek and Zing Pop Culture brands. The company was founded in Dallas in 1984 as Babbage's, and took on its current name in 1999.
Drexel Burnham Lambert Inc. was an American multinational investment bank that was forced into bankruptcy in 1990 due to its involvement in illegal activities in the junk bond market, driven by senior executive Michael Milken. At its height, it was a Bulge Bracket bank, as the fifth-largest investment bank in the United States.
Dennis B. Levine is a corporate consultant and former investment banker. He was a managing director at the investment banking firm Drexel Burnham Lambert in the 1980s. Levine was one of the first of several high-profile insider trading defendants in the Wall Street insider trading investigations of the mid-1980s. As a result of the investigation by and subsequent proceedings, Levine pleaded guilty.
SEC Rule 10b-5, codified at 17 CFR 240.10b-5, is one of the most important rules targeting securities fraud in the United States. It was promulgated by the U.S. Securities and Exchange Commission (SEC), pursuant to its authority granted under § 10(b) of the Securities Exchange Act of 1934. The rule prohibits any act or omission resulting in fraud or deceit in connection with the purchase or sale of any security. The issue of insider trading is given further definition in SEC Rule 10b5-1.
Jefferies Group LLC is an American multinational independent investment bank and financial services company that is headquartered in New York City. The firm provides clients with capital markets and financial advisory services, institutional brokerage, securities research, and asset management. This includes mergers and acquisitions, restructuring, and other financial advisory services. The Capital Markets segment also includes its securities trading and investment banking activities.
Securities fraud, also known as stock fraud and investment fraud, is a deceptive practice in the stock or commodities markets that induces investors to make purchase or sale decisions on the basis of false information. The setups are generally made to result in monetary gain for the deceivers, and generally result in unfair monetary losses for the investors. They are generally violating securities laws.
Life Partners, Inc. is a life settlement provider headquartered in Waco, Texas. LPI's parent company, Life Partners Holdings, Inc., delisted from the NASDAQ, currently trades on the OTCPK under the ticker LPHI.Q. This follows the company seeking Chapter 11 bankruptcy protection, resulting from a total of $46.9 million in penalties levied against the company and two of its officers.
Gabasync is an ineffective treatment promoted for methamphetamine addiction, although it had also been claimed to be effective for dependence on alcohol or cocaine. It was marketed as PROMETA. The treatment, based loosely on research of a Spanish psychologist, involved a combination of three medications as well as therapy. While the individual drugs had been approved by the FDA, their off-label use for addiction treatment has not. Gabasync was marketed by Hythiam, Inc. which is owned by Terren Peizer, a former junk bond salesman who has since been indicted for securities fraud relative to another company. Hythiam has sought to patent the protocol and charges up to $15,000 per patient to license its use. Lower rates are offered to the criminal justice system, where it has been used in drug court pilot programs.
SEC Rule 10b5-1, codified at 17 CFR 240.10b5-1, is a regulation enacted by the United States Securities and Exchange Commission (SEC) in 2000. The SEC states that Rule 10b5-1 was enacted in order to resolve an unsettled issue over the definition of insider trading, which is prohibited by SEC Rule 10b-5.
Dale Susan Fischer is a United States district judge of the United States District Court for the Central District of California. She was nominated by President George W. Bush, and received her commission in 2003.
Frederick H. Joseph was the former president and chief executive officer of the investment bank Drexel Burnham Lambert during the 1980s.
Phillip Frost is an American entrepreneur.
Galena Biopharma was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc.
Dozy Mmobuosi, is a Nigerian businessman and tech entrepreneur. An advocate for technological advancement in Africa, he is the founder and former CEO of Tingo Inc.
{{cite web}}
: CS1 maint: multiple names: authors list (link)